应用二甲双胍联合多西他赛治疗乳腺癌并2型糖尿病患者及提高临床受益率的临床研究

Clinical Study of Metformin Combined with Docetaxel in the Treatment of Breast Cancer Patients with Type 2 Diabetes and Improving the Clinical Benefit Rate

目的分析二甲双胍联合多西他赛治疗乳腺癌并2型糖尿病患者的临床疗效。方法选择该院在2017年10月—2019年10月收治的62例乳腺癌并2型糖尿病患者,行单纯多西他塞治疗的31例为一般组,行多西他赛联合二甲双胍治疗的31例为联合组,比较两组癌变指标、血糖水平及临床受益率。结果联合组VEGF水平为(132.41±5.63)pg/mL,CEA水平为(4.98±0.37)ng/mL;一般组VEGF水平为(161.37±5.18)pg/mL,CEA水平为(7.21±0.56)ng/mL,差异有统计学意义(P<0.05)。联合组RBP4为(29.56±2.17)μg/L,糖化血红蛋白为(5.41±1.03)%,餐后2 h血糖为(6.43±1.39)mmol/L,空腹血糖为(5.07±1.37)mmol/L;一般组RBP4为(31.74±2.25)μg/L,糖化血红蛋白为(7.23±1.42)%,餐后2 h血糖为(7.69±1.18)mmol/L,空腹血糖为(6.43±1.52)mmol/L,差异有统计学意义(P<0.05)。联合组治疗完全缓解的共10例,部分缓解的共12例,稳定的共7例,进展的共2例,临床受益率为93.55%(29例);一般组治疗完全缓解的共8例,部分缓解的共9例,稳定的共6例,进展的共8例,临床受益率为74.19%(23例),差异有统计学意义(P<0.05)。结论将二甲双胍联合多西他赛应用于乳腺癌并2型糖尿病患者的治疗中,能在肿瘤细胞的增殖扩散中发挥抑制作用,降低血糖水平至正常范围,还能有效提升临床受益率。

Objective To analyze the clinical efficacy of metformin combined with docetaxel in the treatment of breast cancer patients with type 2 diabetes.Methods A total of 62 breast cancer patients with type 2 diabetes admitted to the hospital from October 2017 to October 2019 were selected.31 patients treated with docetaxel alone were the general group,and 31 patients treated with docetaxel combined with metformin.In the case of the combined group,the canceration index,blood glucose level and clinical benefit rate of the two groups were compared.Results The VEGF level of the combined group was(132.41±5.63)pg/mL and the CEA level was(4.98±0.37)ng/mL;the VEGF level of the general group was(161.37±5.18)pg/mL and the CEA level was(7.21±0.56)ng/mL,the difference was statistically significant(P<0.05).RBP4 in the combined group was(29.56±2.17)μg/L,glycated hemoglobin was(5.41±1.03)%,postprandial blood glucose was(6.43±1.39)mmol/L,and fasting blood glucose was(5.07±1.37)mmol/L;generally RBP4 was(31.74±2.25)μg/L,glycated hemoglobin was(7.23±1.42)%,postprandial blood glucose was(7.69±1.18)mmol/L,fasting blood glucose was(6.43±1.52)mmol/L,the difference was statistically significant(P<0.05).There were 10 cases of complete remission in the combination group,12 cases of partial remission,7 cases in stable,2 cases in progress,and the clinical benefit rate was 93.55%(29 cases);8 cases in the general group had complete remission,There were 9 cases with partial remission,6 cases with stable,and 8 cases with progress.The clinical benefit rate was 74.19%(23 cases),and the difference was statistically significant(P<0.05).Conclusion The combination of metformin and docetaxel in the treatment of breast cancer and type 2 diabetes patients can play an inhibitory role in the proliferation and spread of tumor cells,reduce blood glucose levels to the normal range,and can effectively improve the clinical benefit rate.